secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2024-09-30T23:59:59+00:00
Accession:  0001104659-24-104002
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis files three new patents for Buntanetap combinations with Trulicity and Viagra
--------------------------------------------------------------------------------

- Patents cover Buntanetap + Trulicity (GLP-1), Buntanetap + Viagra (PDE5i), and triple combo.
- Preclinical synergy data showed cognition in AD mouse models improved beyond healthy controls.
- Combinations positioned for Phase 3 trials; Buntanetap completed Phase 3; Trulicity and Viagra are FDA-approved.
- CEO: combination could restore and improve cognition, offering new hope in dementia fight.
- Annovis expands IP portfolio for neurodegenerative disorders with these filings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924104002/0001104659-24-104002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924104002/tm2425199d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-104002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer